Pin your most used calculators here by clicking the star in the dropdown.
CUETO Risk Score (BCG-Treated)
Clinical Context & Background
The CUETO (Club Urológico Español de Tratamiento Oncológico) model is specifically validated for NMIBC patients treated with BCG immunotherapy. It often provides more accurate (and lower) risk estimates for this population compared to the EORTC tables, which were derived largely from chemotherapy-treated patients.
Formula Logic
Sum of points for Gender, Age, Recurrence Status, Tumors, T-stage, CIS, and Grade.Reference Data
| Score | 5-Year Recurrence Risk | 5-Year Progression Risk |
|---|---|---|
| 0 - 4 | 19.1% | Prog Score 0-6: < 9% |
| 5 - 6 | 35.6% | Prog Score 0-6: < 9% |
| 7 - 8 | 47.5% | Prog Score >6: ~ 15-30% |
| > 8 | 60.5% | Prog Score >6: ~ 15-30% |
Related Tools
Evidence-based oncology decision support. Verify with clinical guidelines.